# Werewolf Therapeutics, Inc.

**HOWL**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001785530

# None

**No letter**

5 of 13 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $69.4M |
| **Warnings** | thin data; fortress balance sheet<br>not computable: degenerate inputs, distress |
| **Inputs computable** | 5 of 13 |
| **Graded from** | filings received through Mar 27, 2026<br>237 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026 |
| **Last close** | $1.01<br>2026-11-18; market equity $49.1M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 27, 2026*

We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINE and INDUCER molecules, are intended to activate selectively in the tumor microenvironment, or TME.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 80.3** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (0.5%) | (6.7%) | | 80.3 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 79.3** | | | | | | |
| Altman Z double-prime | (25.50) | 0.31 | | 79.3 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 1.62x | 2.68x | | 79.4 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 68.7** | | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | | |
| *four annual observations are required; found 0* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 33.9% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (24.3%) | 3.2% | | 88.4 | 663 | 2025-12-31 |
| Net share issuance, one year | 8.4% | 1.6% | | 49.0 | 625 | 2026-03-20 |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 5 of 13 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 24,965,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-11-18 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (29.6%) | (1.7%) | 30 |
| Distance from 52-week high | (6.4%) | (30.2%) | 80 |
| EBIT to enterprise value | (150.7%) | 0.5% | 5 |
| Free cash flow yield | (120.4%) | 0.6% | 6 |
| Book value to price | 0.14 | 0.29 | 30 |
| Sales to price | not computable | 0.36 | |
| Composite equity issuance, five years | not computable | 13.5% | |
| Relative strength against the sector, log excess return | (0.52) | (0.19) | 30 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $41.9M |
| Operating cash flow, four quarters | -$24.0M |
| Months of runway | 21.0 |
| Days since last periodic filing | 6 (10-Q received Nov 13, 2026) |
| Median daily dollar volume, 63 sessions | $465,002 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$60.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$60.3M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 3 | assets | us-gaap:Assets | $69.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 4 | assets | us-gaap:Assets | $126.9M | 2024-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 5 | current assets | us-gaap:AssetsCurrent | $58.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $36.1M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$475.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$60.7M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 9 | book equity | us-gaap:StockholdersEquity | $24.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 10 | liabilities | us-gaap:Liabilities | $44.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 11 | total debt | us-gaap:LongTermDebt | $32.1M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $57.0M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 13 | depreciation amortization | us-gaap:Depreciation | $1.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 14 | operating income | us-gaap:OperatingIncomeLoss | -$40.5M | 2023-12-31 | 2025-03-11 | 10-K | 25-000008 |
| 15 | interest expense | us-gaap:InterestExpense | $3.1M | 2023-12-31 | 2024-03-07 | 10-K | 24-000012 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $0 | 2025-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$56.2M | 2024-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $254,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-000006 |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$32.6M | 2023-12-31 | 2025-03-11 | 10-K | 25-000008 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $769,000 | 2023-12-31 | 2025-03-11 | 10-K | 25-000008 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$40.6M | 2022-12-31 | 2024-03-07 | 10-K | 24-000012 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.6M | 2022-12-31 | 2024-03-07 | 10-K | 24-000012 |
| 23 | assets | us-gaap:Assets | $174.8M | 2023-12-31 | 2025-03-11 | 10-K | 25-000008 |
| 24 | assets | us-gaap:Assets | $160.2M | 2022-12-31 | 2024-03-07 | 10-K | 24-000012 |
| 25 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 48,596,817 | 2026-03-20 | 2026-03-27 | 10-K | 26-000006 |
| 26 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 44,827,159 | 2025-03-05 | 2025-03-11 | 10-K | 25-000008 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.